Lung Cancer Surgery Market to Reach USD 8,297.8 Million by 2031, Growing at 4.12% CAGR

As lung cancer continues to rank among the deadliest cancers worldwide, surgical innovation is playing an increasingly central role in improving patient outcomes. According to the lung cancer surgery market report, the global industry was valued at USD 6,039.3 million in 2023 and is projected to grow from USD 6,255.9 million in 2024 to USD 8,297.8 million by 2031, registering a CAGR of 4.12% during the forecast period. Growth is being driven by rising incidence rates, rapid technological advancement, and increasing investment in healthcare infrastructure across both developed and emerging markets.

The Scale of the Challenge

Lung cancer surgery refers to the procedures performed to treat lung cancer by removing cancerous tumors or affected lung tissue, forming a crucial component of treatment for patients diagnosed with the disease. The type of surgery performed depends on factors such as tumor size and location, patient health, and cancer stage, with common approaches including lobectomy, segmentectomy, and wedge resection. Increasingly, minimally invasive and robotic-assisted techniques are being used to enhance surgical precision and reduce patient recovery times.

The scale of unmet need underscores why this market continues to expand. According to data published by the American Cancer Society in 2022, lung cancer — including both small cell and non-small cell types — ranks as the second most prevalent cancer in both men and women, accounting for nearly 25% of all cancer-related deaths. The World Health Organization further reports that smoking is responsible for approximately 85% of all lung cancer cases, highlighting the ongoing public health burden driving demand for surgical intervention.

AI-Driven Diagnostics Are Transforming Early Detection

A significant factor supporting market progress is the integration of advanced diagnostic tools and technologies. AI-driven tools such as Sybil, which accurately predicts lung cancer risk with high precision, are enhancing early detection capabilities in ways that are crucial for improving patient outcomes through earlier intervention and treatment. Earlier detection directly translates into more surgical candidates and better prognoses, reinforcing demand across the surgical device and instrument ecosystem.

Key market players continue to advance through strategic partnerships and technological innovation. VOCxi Health’s collaboration with Silicon & Software Systems Ltd. aims to pioneer new lung cancer detection and monitoring devices with a focus on enhancing diagnostic accuracy and clinical application. Meanwhile, public health initiatives such as the NHS’s “Help Us Help You” campaign are working to educate at-risk populations about the importance of early detection — a critical factor for effective treatment outcomes.

Personalized Medicine and Immunotherapy Reshape Treatment Pathways

The growing shift toward personalized medicine is a notable trend significantly propelling market growth. Advances in genomics and molecular biology have enabled targeted therapies that specifically attack cancer cells carrying certain genetic mutations, such as EGFR, ALK, and ROS1, leading to more effective treatments with fewer side effects compared to traditional chemotherapy. As patient outcomes improve, demand for molecular diagnostics and targeted therapies increases correspondingly, requiring surgical interventions that align precisely with the genetic profile of each patient’s tumor.

Immunotherapy is rapidly gaining traction as a transformative treatment approach as well. Immune checkpoint inhibitors, including pembrolizumab and nivolumab, have demonstrated significant efficacy in treating certain lung cancer types by enhancing the body’s immune response against cancer cells. Their success in clinical trials and subsequent regulatory approval is fostering further research and expanding the use of immunotherapy both as a standalone treatment and in combination with chemotherapy and targeted therapies — integration that is enhancing surgical outcomes and reducing recurrence rates.

High Treatment Costs Remain a Barrier

The high cost of treatment continues to hinder market growth, particularly affecting patient access to advanced surgical techniques and innovative therapies such as immunotherapy. These expenses pose significant barriers in regions with limited healthcare resources and inadequate insurance coverage. Key players are responding by forming partnerships with healthcare providers, insurers, and governmental agencies to develop cost-effective solutions such as bundled payment models and value-based care programs, alongside significant R&D investment aimed at enhancing surgical technology and treatment efficiency. Many companies are also implementing patient assistance programs, offering subsidies, grants, and flexible payment options to improve treatment accessibility.

Segment Performance: Thoracotomy and Surgical Instruments Lead

By surgical procedure, thoracotomy generated the highest revenue in 2023, at USD 3,952.7 million, owing to its essential role in treating complex and advanced-stage lung cancers. Despite the rise of minimally invasive techniques, thoracotomy remains crucial for accessing and treating larger tumors effectively, particularly in cases requiring more extensive surgical intervention. By surgical devices, the surgical instruments segment captured the largest share in 2023, at 54.34%, encompassing tools used across thoracotomy, video-assisted thoracoscopic surgery (VATS), and robotic-assisted procedures, with ongoing technological advancements enhancing precision and reducing post-operative complications.

Regional Analysis: North America Leads, Asia-Pacific Grows Fastest

North America held the largest regional share in 2023, at approximately 35.67% and a valuation of USD 2,154.2 million. The region benefits from a high prevalence of lung cancer alongside advanced healthcare infrastructure, particularly in the United States, supported by substantial healthcare spending and comprehensive insurance coverage. Rapid adoption of cutting-edge diagnostic and therapeutic technologies, including molecular targeted therapies and immunotherapies, is aiding continued market expansion, alongside robust R&D activity backed by stringent regulatory frameworks.

Asia-Pacific is anticipated to witness the highest growth, registering a CAGR of 5.00% over the forecast period, with market value projected to reach USD 1,912.8 million by 2031. China, Japan, and India are key contributors, driven by rising pollution levels, high smoking rates, and an aging population. The region is seeing substantial healthcare investment leading to improved access to diagnostic and treatment facilities, with governments implementing policies to enhance cancer care and increase public awareness, while growth in the regional pharmaceutical industry is making treatments more accessible through affordable generic drugs.

Competitive Landscape

The market remains fragmented, with prominent players focusing on partnerships, mergers and acquisitions, product innovations, and joint ventures to expand their portfolios and increase market share. Major companies operating in the market include Accuray Incorporated, AngioDynamics, Intuitive Surgical, Olympus America, Teleflex Incorporated, Karl Storz SE & Co, Siemens Healthcare Private Limited, Medtronic, Wexler Surgical, and Richard Wolf GmbH.

A notable industry development came in March 2023, when AstraZeneca (Thailand) Company Limited signed a Memorandum of Understanding with Phyathai 2 Hospital to implement AI-based technology for chest X-rays as part of the “Advancing Early Lung Cancer Screening with AI Technology” campaign, aimed at improving the efficiency of early-stage lung cancer screening and raising awareness of regular health check-ups.

Outlook

As diagnostic AI tools continue improving early detection rates and personalized medicine reshapes treatment pathways, the lung cancer surgery market is set for steady, sustained growth through 2031. While the high cost of advanced treatment remains a real barrier to broader access, ongoing investment in patient assistance programs and value-based care models suggests the industry is actively working to close that gap — particularly across fast-growing markets in Asia-Pacific.